Novartis' Kisqali drug is the first approved by the US Food and Drug Administration (FDA) under its new oncology drug pilot, which aims to make the development and review of cancer drugs more proficient.
The post Novartis Notches First FDA Nod Through New Oncology Review Pilot appeared first on Investing News Network.
Original Article: Novartis Notches First FDA Nod Through New Oncology Review Pilot